J Q Trojanowski


Affiliation: University of Pennsylvania
Country: USA


  1. Trojanowski J, Vandeerstichele H, Korecka M, Clark C, Aisen P, Petersen R, et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010;6:230-8 pubmed publisher
    ..Further studies in ADNI will refine this model and render the biomarkers studied in ADNI more applicable to routine diagnosis and to clinical trials of disease modifying therapies. ..
  2. Toledo J, Bjerke M, Chen K, Rozycki M, Jack C, Weiner M, et al. Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings. Neurology. 2015;85:144-53 pubmed publisher
  3. McMillan C, Irwin D, Nasrallah I, Phillips J, Spindler M, Rascovsky K, et al. Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 2016;132:935-937 pubmed
  4. Toledo J, Van Deerlin V, Lee E, Suh E, Baek Y, Robinson J, et al. A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimers Dement. 2014;10:477-484.e1 pubmed publisher
    ..We describe a biobanking system that is a platform for discovery research at the Center for Neurodegenerative Disease Research at the University of Pennsylvania. ..
  5. Toledo J, Weiner M, Wolk D, Da X, Chen K, Arnold S, et al. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun. 2014;2:26 pubmed publisher
    ..The newly defined SCINIB category of ADNI subjects is more prevalent than AD preclinical stage individuals. ..
  6. Robinson J, Molina Porcel L, Corrada M, Raible K, Lee E, Lee V, et al. Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old. Brain. 2014;137:2578-87 pubmed publisher
  7. Toledo J, Zetterberg H, van Harten A, Glodzik L, Martinez Lage P, Bocchio Chiavetto L, et al. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain. 2015;138:2701-15 pubmed publisher
  8. Stutzbach L, Xie S, Naj A, Albin R, Gilman S, Lee V, et al. The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease. Acta Neuropathol Commun. 2013;1:31 pubmed publisher
    ..The UPR is activated in disease affected regions in PSP and the genetic evidence shows that this activation increases risk for PSP and is not a protective response. ..
  9. Busch J, Martinez Lage M, Ashbridge E, Grossman M, Van Deerlin V, Hu F, et al. Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain. Acta Neuropathol Commun. 2013;1:36 pubmed publisher
    ..In addition, we demonstrate that FTLD-TDP cases with GRN mutations exhibit a loss of neuronal TMEM106B subcellular localization, adding to evidence that TMEM106B and progranulin may be pathophysiologically linked in FTLD-TDP. ..

More Information


  1. Trojanowski J, Lee V. The role of tau in Alzheimer's disease. Med Clin North Am. 2002;86:615-27 pubmed
  2. Trojanowski J, Lee V. Parkinson's disease and related synucleinopathies are a new class of nervous system amyloidoses. Neurotoxicology. 2002;23:457-60 pubmed
    ..Continuing advances in this research direction should advance understanding of PD and accelerate discovery of more effective therapies for this and related synucleinopathies. ..